Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 14, 2024 16:00 ET
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
$1.6+ Billion Anti-Venom Markets - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F: Next-Generation Anti-Venoms & Precision Medicine Approaches
May 13, 2024 10:52 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Anti-Venom Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's...
Global Hepatitis B Vaccines Business Research Report 2024: Market to Reach $3.9 Billion by 2030 from $2.9 Billion in 2023 with Combination Vaccines Accounting for $2.6 Billion
May 13, 2024 09:58 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Hepatitis B Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Hepatitis B Vaccines Market...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:05 ET
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...
Dyadic to Attend Industry and Investor Events in May
May 08, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Infectious Vaccine Collaboration, Development, Research and Licensing Deals Trends Report 2024 with Directory of 522 Agreements Signed Since 2019
May 07, 2024 06:37 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Infectious Vaccine...
Global Vaccine Delivery Devices Market Report 2024-2032: Device, Route of Administration, End User, and Regional Analysis and Forecasts
May 07, 2024 05:24 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Delivery Devices Market Report by Device, Route of Administration, End User, and Region 2024-2032" report has been added to ...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
May 02, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Global Anti-Venom Analysis Report 2024: A $1.95 Billion Market by 2032 Featuring BSV, Boehringer Ingelheim, Boston Scientific, CSL, Merck, Pfizer, Haffkine Bio-Pharmaceutical
April 30, 2024 10:37 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-Venom Market Report by Type, Animal Type, End User, Region and Company Analysis 2024-2032" report has been added to ...
Pfizer's ABRYSVO (RSVpreF) for Respiratory Syncytial Virus (RSV) in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2023-2032
April 30, 2024 04:40 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "ABRYSVO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...